期刊文献+

孕激素辅助治疗术后高危型子宫内膜癌的临床病理分析 被引量:8

下载PDF
导出
摘要 目的:评估孕激素辅助治疗术后高危型子宫内膜癌的效果及预后因素。方法:回顾性分析我院2005年1月至2013年5月收治的268例早期高危型及晚期子宫内膜癌患者的病历资料,根据术后是否使用孕激素治疗分为孕激素组(132例)和对照组(136例)。采用χ2检验,Kaplan-Meier生存分析比较两组的生存率和复发率。Cox多因素分析子宫内膜癌术后孕激素辅助治疗疗效的影响因素。结果:孕激素组和对照组患者的5年生存率分别为82.6%%和77.9%,5年复发率分别为21.9%和27.2%,两组比较差异均有统计学意义(P<0.05)。多因素分析提示,孕激素受体、病理分级、孕激素使用是否超过1年是影响激素治疗疗效的独立危险因素。结论:子宫内膜癌术后激素治疗对于提高患者的长期生存率有明显影响,术后根据患者孕激素受体、病理分级的情况应用孕激素辅助治疗,可以改善患者的预后。
出处 《广西医科大学学报》 CAS 2015年第1期93-95,共3页 Journal of Guangxi Medical University
基金 广西医疗卫生重点科研课题(No.重2012094)
  • 相关文献

参考文献10

  • 1Jobo T, Kawaguchi M, Imai M, et al. Treatment for complex atypical hyperplasia of the endometrium[J]. European Journal of Gynaecological Oncology, 2001,22 (5) :365-368.
  • 2Garrett A, Quinn MA. Hormonal therapies and gynae- cological cancers[J]. Best Pract Res Clin Obstet Gynaecol,2008,22(2) :407-421.
  • 3Kim MK, Yoon BS, Park H, et al. Conservative treat- ment with medroxyprogesterone acetate plus levonorg estrel intrauterine system {or early-stage endometrial cancer in young women: pilot study[J]. Int J Gynecol Cancer, 2011,21 (4) : 673-677.
  • 4Thigpen JT, Brady MF, Alvarez RD, et al. Oral me- droxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Ontology Group[J]. J Clin Oncol,1999,17(6) :1 736-1 744.
  • 5王志启,王建六,郭健,魏丽惠.内分泌辅助治疗子宫内膜癌的临床意义[J].中华医学杂志,2005,85(34):2414-2419. 被引量:21
  • 6Von Minckwitz G, Loibl S, Brunnert K, et al. Adju vant endocrine treatment with medroxyprogesterone ae etate or tamoxifen in stage I and II endometrial cancera multicentre, open, controlled, prospectively random- ised trial[J]. EurJ Cancer,2002,38(17):2 265-2 271.
  • 7Yang YC, Wu CC, Chen CP, et al. Reevaluating the safety of fertility sparing hormonal therapy for early endometrial cancer[J]. Gynecologic Ontology,2005,99 (2) :287-293.
  • 8高敏,魏丽惠,孙蓬明,赵丹,李小平.雌激素受体相关受体α和雌激素受体α在子宫内膜癌中的表达及临床意义[J].北京大学学报(医学版),2006,38(5):463-465. 被引量:14
  • 9Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Pro- gestagens for endometrial cancer[J]. Cochrane Database Syst Rev,2000,(2):CD001040.
  • 10Gruber T, Dare AO, Balos LL, et al. Multiple menin giomas arising during long-term therapy with the pro gesterone agonist megestrol acetate. Case report [J] Journal of Neurosurgery, 2004,100(2) : 328-331.

二级参考文献21

  • 1Gruber T, Dare AO, Balos LL, et al. Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report. J Neurosurg,2004, 100:328-331.
  • 2Makarov OV, Sergeev PV, Sviridov NK, et al. Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia. Vopr Onkol,2000,46:570-573.
  • 3Nola M, Jukic S, Ilic-Forko J, et al. Effects of tamoxifen on steroid hormone receptors and hormone concertration and the results of DNA analysis bu flow cytometry in endometrial carcinoma. Gynecol Oncol,1999,72:331-336.
  • 4Jobo T, Kawaguchi M, Imai M, et al. Treatment for complex atypical hyperplasia of the endometrium. Eur J Gynaecol Oncol,2001,22:365-368.
  • 5Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol,1999,17:1736-1744.
  • 6Imai M, Jobo T, Sato R, et al. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol,2001,22:217-220.
  • 7Mikuta JJ. International Federation of Gynecology and Obstertrics staging of endometrial cancer 1988. Cancer, 1993, 71:1460-1463.
  • 8von Minckwitz G, Loibl S, Brunnert K, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer,2002,38:2265-2271.
  • 9Vishnevsky AS, Bokhman YaV, Loutfi G. Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. Eur J Gynaecol Oncol,1993,14:150-153.
  • 10Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol,2004,92:10-14.

共引文献31

同被引文献70

引证文献8

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部